Wedbush Has Pessimistic View of Ardelyx FY2026 Earnings

Ardelyx, Inc. (NASDAQ:ARDX) – Investment analysts at Wedbush decreased their FY2026 earnings per share estimates for shares of Ardelyx in a report issued on Tuesday, October 14th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will post earnings per share of $0.05 for the year, down from their previous estimate of $0.06. Wedbush has a “Outperform” rating and a $14.00 price objective on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share. Wedbush also issued estimates for Ardelyx’s Q4 2026 earnings at $0.05 EPS, FY2027 earnings at $0.40 EPS and FY2028 earnings at $0.68 EPS.

Ardelyx (NASDAQ:ARDX) last released its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.05. The company had revenue of $97.66 million for the quarter, compared to analyst estimates of $82.69 million. Ardelyx had a negative net margin of 14.60% and a negative return on equity of 36.57%. The firm’s revenue was up 23.0% on a year-over-year basis. During the same period last year, the firm earned ($0.07) earnings per share.

A number of other equities analysts also recently weighed in on ARDX. Piper Sandler boosted their price target on shares of Ardelyx from $8.00 to $9.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. UBS Group set a $12.00 target price on shares of Ardelyx in a research report on Tuesday, August 5th. Raymond James Financial started coverage on shares of Ardelyx in a report on Wednesday, September 3rd. They issued a “strong-buy” rating and a $14.00 price target on the stock. Wall Street Zen raised Ardelyx from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Ardelyx in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Ardelyx currently has an average rating of “Moderate Buy” and a consensus target price of $11.70.

Ardelyx Stock Performance

Shares of ARDX opened at $5.13 on Wednesday. The stock has a 50 day moving average of $5.90 and a 200 day moving average of $4.80. The company has a current ratio of 4.30, a quick ratio of 4.03 and a debt-to-equity ratio of 1.44. Ardelyx has a 12 month low of $3.21 and a 12 month high of $6.78. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -22.30 and a beta of 0.67.

Insider Activity at Ardelyx

In related news, insider Eric Duane Foster sold 15,308 shares of the company’s stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $5.93, for a total transaction of $90,776.44. Following the sale, the insider owned 301,498 shares of the company’s stock, valued at approximately $1,787,883.14. This represents a 4.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Justin A. Renz sold 7,037 shares of the business’s stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $5.93, for a total transaction of $41,729.41. Following the transaction, the chief financial officer owned 409,052 shares of the company’s stock, valued at $2,425,678.36. This trade represents a 1.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 165,551 shares of company stock valued at $996,917 in the last quarter. 4.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Ardelyx

A number of hedge funds and other institutional investors have recently bought and sold shares of ARDX. GAMMA Investing LLC lifted its holdings in shares of Ardelyx by 1,342.0% during the 1st quarter. GAMMA Investing LLC now owns 5,912 shares of the biopharmaceutical company’s stock worth $290,000 after acquiring an additional 5,502 shares during the last quarter. Rhumbline Advisers lifted its stake in Ardelyx by 4.1% during the first quarter. Rhumbline Advisers now owns 339,436 shares of the biopharmaceutical company’s stock worth $1,667,000 after purchasing an additional 13,312 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of Ardelyx by 203.1% in the 1st quarter. SG Americas Securities LLC now owns 166,343 shares of the biopharmaceutical company’s stock worth $817,000 after purchasing an additional 111,457 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of Ardelyx by 87.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 53,336 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 24,893 shares during the last quarter. Finally, Cyndeo Wealth Partners LLC purchased a new position in shares of Ardelyx during the 1st quarter valued at about $49,000. Hedge funds and other institutional investors own 58.92% of the company’s stock.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.